SEGMENT REPORTING

12 Months Ended

Dec. 31, 2013

SEGMENT REPORTING [Text Block]

18. SEGMENT REPORTING

As defined in ASC Topic 280, “Segment Reporting”, the Company has three operating segments, and two reportable segments, including Chaoying Biotech and SD Chaoying. Chaoying Biotech is primarily in the business of researching, producing, and selling of high-quality tissue arrays and providing related services. SD Chaoying mainly focused on real estate development and intended to operate a cultural and entertainment center which will encompass a wide variety of recreational and commercial activities. Earnings performance is measured using segment operating income.

		Years Ended December 31,
		2013		2012
Revenues:
Chaoying Biotech	$	574,261	$	514,593
SD Chaoying		-		268,582
Others		-		-
Total Revenues	$	574,261	$	783,175

		Years Ended December 31,
		2013		2012
Segment loss:
Chaoying Biotech	$	(62,734	$	(121,753
SD Chaoying		(334,939		(304,170
Others		(219,074		(229,717
Loss before Income Taxes	$	(616,747	$	(655,640

		Years Ended December 31,
		2013		2012
Total Assets:
Chaoying Biotech	$	714,925	$	1,460,233
SD Chaoying		9,584,273		9,006,220
Others		53,544		85,055
Total assets	$	10,352,742	$	10,551,508

The following sets forth geographic information relating to the Company’s revenues from external customers attributed to the Company’s country of domicile, China, and attributed to foreign countries.

		Years Ended December 31,
		2013		2012
United States	$	417,082	$	450,042
China		157,179		333,133
Total revenue	$	574,261	$	783,175

All revenues are from external customers. One major customer from the United States accounted for 73% and 57% of our total revenues for the years ended December 31, 2013 and 2012. All long-lived assets are located in China.